What's in GATT Technologies BV's pipeline?

GATT Technologies BV has 1 drugs in our index: 1 marketed, 0 filed, 0 in Phase 3, 0 in Phase 2, 0 in Phase 1.

Which companies overlap with GATT Technologies BV's portfolio?

Top competitors by shared drug class: Baxter Healthcare Corporation, Ethicon, Inc., Grifols Biologicals, LLC, IBON JAUNARENA, Samsung Medical Center.

How do I subscribe to ongoing alerts?

Subscribe to /feed/company/gatt-technologies-bv.xml in any RSS reader. Every regulatory action and pipeline update lands in your feed.

Last reviewed 2026-05-14 · How we verify

GATT Technologies BV — Portfolio Competitive Intelligence Brief

GATT Technologies BV pipeline: 1 marketed, 0 filed, 0 Phase 3, 0 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

1 marketed 0 filed 0 Phase 3 0 Phase 2 0 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

Drug	Generic	Phase	Class	Target	Area	First approval
TachoSil	TachoSil	marketed	Hemostatic agent / Fibrin sealant	Fibrinogen (conversion to fibrin via thrombin)	Surgery / Hemostasis

Therapeutic area mix

Surgery / Hemostasis · 1

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

Baxter Healthcare Corporation · 1 shared drug class
Ethicon, Inc. · 1 shared drug class
Grifols Biologicals, LLC · 1 shared drug class
IBON JAUNARENA · 1 shared drug class
Samsung Medical Center · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for GATT Technologies BV:

Cite this brief

Drug Landscape (2026). GATT Technologies BV — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/gatt-technologies-bv. Accessed 2026-05-14.